Serum uric acid and the risk of cardiovascular and renal disease
Substantial evidence suggests that chronic hyperuricemia is an independent risk factor for
hypertension, metabolic syndrome, chronic kidney disease (CKD) and cardiovascular …
hypertension, metabolic syndrome, chronic kidney disease (CKD) and cardiovascular …
Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease
During the last century, there has been an increasing prevalence of hyperuricaemia noted in
many populations. While uric acid is usually discussed in the context of gout …
many populations. While uric acid is usually discussed in the context of gout …
Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age?
JT Kielstein, C Zoccali - American Journal of Kidney Diseases, 2005 - Elsevier
The idea that asymmetric dimethylarginine (ADMA) accumulation may be a cardiovascular
risk factor in patients with end-stage renal disease was advanced by Vallance in 1992 …
risk factor in patients with end-stage renal disease was advanced by Vallance in 1992 …
[HTML][HTML] Drug dosing consideration in patients with acute and chronic kidney disease—a clinical update from Kidney Disease: Improving Global Outcomes (KDIGO)
GR Matzke, GR Aronoff, AJ Atkinson Jr, WM Bennett… - Kidney international, 2011 - Elsevier
Drug dosage adjustment for patients with acute or chronic kidney disease is an accepted
standard of practice. The challenge is how to accurately estimate a patient's kidney function …
standard of practice. The challenge is how to accurately estimate a patient's kidney function …
Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans
JT Kielstein, B Impraim, S Simmel, SM Bode-Böger… - Circulation, 2004 - Am Heart Assoc
Background—Increased blood concentrations of the endogenous nitric oxide synthase
(NOS) inhibitor asymmetrical dimethylarginine (ADMA) have been linked to excess …
(NOS) inhibitor asymmetrical dimethylarginine (ADMA) have been linked to excess …
Validation of treatment strategies for enterohaemorrhagic Escherichia coli O104: H4 induced haemolytic uraemic syndrome: case-control study
J Menne, M Nitschke, R Stingele, M Abu-Tair, J Beneke… - Bmj, 2012 - bmj.com
Objective To evaluate the effect of different treatment strategies on enterohaemorrhagic
Escherichia coli O104: H4 induced haemolytic uraemic syndrome. Design Multicentre …
Escherichia coli O104: H4 induced haemolytic uraemic syndrome. Design Multicentre …
Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease
JANT KIELSTEIN, RH BO, SM BODE-BO… - Journal of the …, 1999 - journals.lww.com
Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of endothelial nitric oxide
(NO) synthase. Its concentration is elevated in patients with end-stage renal disease …
(NO) synthase. Its concentration is elevated in patients with end-stage renal disease …
Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease
JT Kielstein, RH Bo, SM Bode-Bo, H Haller… - Journal of the …, 2002 - journals.lww.com
In patients with uremia, increased blood concentrations of the endogenous nitric oxide
synthase inhibitor asymmetric dimethylarginine (ADMA) have been linked to the severity of …
synthase inhibitor asymmetric dimethylarginine (ADMA) have been linked to the severity of …
Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study
B Becker, F Kronenberg, JT Kielstein… - Journal of the …, 2005 - journals.lww.com
The relationship among insulin resistance, adiponectin, and cardiovascular (CV) morbidity
in patients with mild and moderate kidney disease was investigated. Insulin sensitivity …
in patients with mild and moderate kidney disease was investigated. Insulin sensitivity …
Symmetric dimethylarginine (SDMA) as endogenous marker of renal function—a meta-analysis
JT Kielstein, SR Salpeter… - Nephrology Dialysis …, 2006 - academic.oup.com
Background. Dosing of most drugs must be adapted in renal insufficiency, making accurate
assessment of renal function essential in clinical medicine. Furthermore, even modest …
assessment of renal function essential in clinical medicine. Furthermore, even modest …